SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Abstract

SARS-CoV-2 variants with spike (S)-protein D614G mutations now predominate globally. We therefore compare the properties of the mutated S protein (S G614 ) with the original (S D614 ). We report here pseudoviruses carrying S G614 enter ACE2-expressing cells more efficiently than those with S D614 . This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion. Similar results are obtained with virus-like particles produced with SARS-CoV-2 M, N, E, and S proteins. However, D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may increase infectivity by assembling more functional S protein into the virion.

References 40

1. 1.

   Li W, Choe H, Farzan M. Insights from the association of SARS-CoV S-protein with its receptor, ACE2. Adv. Exp. Med. Biol. 2006;581:209-218.

   Not in our library10.1007/978-0-387-33012-9_36

2. 2.

   Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1-23.

   Not in our library10.1007/978-1-4939-2438-7_1

3. 3.

   Shang J, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221-224.

   Not in our library10.1038/s41586-020-2179-y

4. 4.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
5. 5.

   Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181, P281–292.E6 (2020).

   Not in our library10.1016/j.cell.2020.02.058

6. 6.

   Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215-220.

   Not in our library10.1038/s41586-020-2180-5

7. 7.

   Wang Q, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894-904.

   Not in our library10.1016/j.cell.2020.03.045

8. 8.

   Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.

   Not in our library10.1038/nature02145

9. 9.

   Li W, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24:1634-1643.

   Not in our library10.1038/sj.emboj.7600640

10. 10.
    A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2 · 2004

    No notice
11. 11.

    Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864-1868.

    Not in our library10.1126/science.1116480

12. 12.
    Cell entry mechanisms of SARS-CoV-2 · 2020

    No notice
13. 13.

    Glowacka I, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 2011;85:4122-4134.

    Not in our library10.1128/jvi.02232-10

14. 14.
    SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells · 2006

    No notice
15. 15.

    Matsuyama S, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010;84:12658-12664.

    Not in our library10.1128/jvi.01542-10

16. 16.

    Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120-134.

    Not in our library10.1016/j.virusres.2014.11.021

17. 17.

    Shulla A, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 2011;85:873-882.

    Not in our library10.1128/jvi.02062-10

18. 18.

    Simmons G, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA. 2005;102:11876-11881.

    Not in our library10.1073/pnas.0505577102

19. 19.

    Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl Acad. Sci. USA. 2009;106:5871-5876.

    Not in our library10.1073/pnas.0809524106

20. 20.

    Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181, 271–280.e8. (2020).

    Not in our library10.1016/j.cell.2020.02.052

21. 21.

    Júnior, I. J. M., Polveiro, R. C., Souza, G. M., Inserra, D. & Bortolin, F. T. S., Lima A. T. M. The global population of SARS-CoV-2 is composed of six major subtypes. bioRxiv, 10.1101/2020.04.14.040782 (2020).

    Not in our library10.1038/s41598-020-74050-8

22. 22.

    Korber, B. et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell182, 812–827 (2020).

    Not in our library10.1016/j.cell.2020.06.043

23. 23.

    Laha, S. et al. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect. Genet. Evol.85, 104445. 10.1016/j.meegid.2020.104445 (2020).

    Not in our library10.1016/j.meegid.2020.104445

24. 24.

    Laamarti, M. et al. Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations. bioRxiv, 10.1101/2020.05.03.074567.

    Not in our library10.1371/journal.pone.0240345

25. 25.

    Lokman, S. M. et al. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: a computational biology approach. bioRxiv,10.1101/2020.04.07.030924 (2020).

    Not in our library10.1016/j.meegid.2020.104389

26. 26.

    Comandatore, F. et al. Insurgence and worldwide diffusion of genomic variants in SARS-CoV-2 genomes. bioRxiv, 10.1101/2020.04.30.071027 (2020).

    Not in our library

27. 27.

    Zhang, L. et al. Genome-wide variations of SARS-CoV-2 infer evolution relationship and transmission route. bioRxiv, 10.1101/2020.04.27.20081349 (2020).

    Not in our library

28. 28.
    No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2 · 2020

    No notice
29. 29.

    Bhowmik, D., Pal, S., Lahiri, A., Talukdar, A. & Paul, S. Emergence of multiple variants of SARS-CoV-2 with signature structural changes. bioRxiv, 10.1101/2020.04.26.062471 (2020).

    Not in our library

30. 30.

    Cortey, M. et al. SARS-CoV-2 amino acid substitutions widely spread in the human population are mainly located in highly conserved segments of the structural proteins. bioRxiv, 10.1101/2020.05.16.099499 (2020).

    Not in our library

31. 31.

    Muller, N.F. et al. Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State. medRxiv10.1101/2020.09.30.20204230 (2020).

    Not in our library10.1126/scitranslmed.abf0202

32. 32.

    Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78:779-784.

    Not in our library10.1016/j.molcel.2020.04.022

33. 33.
    SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells · 2020

    No notice
34. 34.

    Muss, C. et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv, 10.1101/2020.04.19.049254 (2020).

    Not in our library

35. 35.
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues · 2020

    No notice
36. 36.
    Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV · 2020

    Corrected
37. 37.

    Huang Y, Yang ZY, Kong WP, Nabel GJ. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J. Virol. 2004;78:12557-12565.

    Not in our library10.1128/jvi.78.22.12557-12565.2004

38. 38.

    Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.

    Not in our library10.1126/science.abb2507

39. 39.

    Moore MJ, et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J. Virol. 2004;78:10628-10635.

    Not in our library10.1128/jvi.78.19.10628-10635.2004

40. 40.

    De Genst EJ, et al. Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody. J. Mol. Biol. 2010;402:326-343.

    Not in our library10.1016/j.jmb.2010.07.001

Cited by papers we hold 38

• SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines · 2022
  No notice
• Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core · 2022
  Not checked
• Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India · 2022
  Not checked
• Mutations and Evolution of the SARS-CoV-2 Spike Protein · 2022
  Corrected
• COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
  No notice
• Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies · 2022
  No notice
• Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development · 2021
  No notice
• Surge of severe acute respiratory syndrome coronavirus 2 infections linked to single introduction of a virus strain in Myanmar, 2020 · 2021
  Not checked
• Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
  Not checked
• SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia · 2021
  Not checked
• SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera · 2021
  Not checked
• Single base mutations in the nucleocapsid gene of SARS-CoV-2 affects amplification efficiency of sequence variants and may lead to assay failure · 2021
  Not checked
• Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines · 2021
  Not checked
• The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic · 2021
  No notice
• Structural impact on SARS-CoV-2 spike protein by D614G substitution · 2021
  No notice
• The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2 · 2021
  Corrected
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine · 2021
  No notice
• Emerging SARS-CoV-2 variants of concern and potential intervention approaches · 2021
  No notice
• mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
  No notice

and 18 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.